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Abstract The primary objective of this trial was to assess the
feasibility, toxicity profile, and antitumor activity of
gemtuzumab ozogamicin (GO) combined with a chemothera-
py remission-induction regimen in adults with untreated high-
risk myelodysplastic syndrome (HR-MDS) or secondary
acute myeloid leukemia (sAML). In this phase II trial, 30
patients with median age of 58 years received 1 day of GO
as a 1-h infusion at the dose level of 5 mg/m2 on day 7 of the
remission-induction course further consisting of a continuous
infusion of cytarabine 100 mg/m2/day for 10 days and
idarubicin 12 mg/m2/day on days 1, 3, and 5. A consolidation
course, consisting of intermediate-dose cytarabine (A) and
idarubicin (I) followed by hematopoietic stem cell transplan-
tation (HSCT) was planned for patients in complete remission
(CR). The primary endpoints were response rate (CR/CRi)
and severe toxicity rate. The secondary endpoint(s) were sur-
vival and progression-free survival (PFS) from start of treat-
ment. Thirteen patients (43 %) achieved CR (eight patients) or
CR with incomplete hematopoietic recovery (CRi) (five pa-
tients). In patients who achieved CR or CRi, the median time
to recovery of neutrophils to 0.5×109/l and of platelets to
>50×109/l was 29 and 30 days, respectively. Grade 3 to 4
severe toxicities occurred in nine patients. The most promi-
nent was liver toxicity, as shown by elevated bilirubin levels in
16 patients and one case of nonfatal veno-occlusive disease
(VOD). All 13 patients with CR/CRi received consolidation
therapy, which was followed by allogeneic HSCT in five pa-
tients and autologous HSCT in three patients. According to
the statistical design of the study, the idarubicin and cytarabine
in combination with gemtuzumab ozogamicin (IAGO) regi-
men did not show sufficient activity to warrant further explo-
ration of this regimen in adult patients with HR-MDS or
sAML.
Keywords High-riskmyelodysplastic syndromes .
Secondary acute myeloid leukemia . Gemtuzumab
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Introduction
AML-like therapy for patients with high-risk myelodysplastic
syndrome (MDS) has been accepted less widely than for patients
with de novo AML [1, 2]. The European LeukemiaNet guide-
lines on MDS recommend that induction chemotherapy should
be considered for fit patients without a suitable donor who are
younger than age 65 to 70 years and have 10 % or more bone
marrow blasts without adverse cytogenetic characteristics [3].
Prognostic factors for outcome after AML-like therapy in
MDS have been studied less frequently than in de novo AML
[2, 4–6]. Cytogenetic abnormalities, age, antecedent
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hematological disease (AHD), performance status, and applied
treatment are prognostic factors for survival and event-free sur-
vival (EFS) [7]. The results of intensive chemotherapy in patients
with advanced stages of MDS have improved with complete
remission (CR) rates now ranging between 44 and 64 % [4,
7–11]. Remission after chemotherapy usually lasts less than
12 months [9, 12]. The higher incidence of adverse cytogenetic
characteristics and the higher expression of the multidrug resis-
tance 1 gene (MDR1) in MDS compared to de novo AML may
explain the inferior response to chemotherapy [13–16].
The rationale for this study was to improve eradication of the
malignant clones in high-risk MDS and secondary AML
(sAML). Incomplete eradication of these clones is the main
cause of treatment failure demonstrated as a relatively low CR
rate and a high early relapse rate of more than 50 %, unless
treated by allogeneic hematopoietic stem cell transplantation
(HSCT). Therefore, new studies should focus on new and better
remission-induction and consolidation regimens. For the devel-
opment of a new prospective, randomized study, it is necessary
to perform phase II studies. We decided to test a new reduction-
remission regimen as primary treatment in the same patient pop-
ulation participating in a previousMDS study [17].We elected to
incorporate gemtuzumab ozogamicin (GO) into regular
remission-induction regimen. GO consists of a humanized anti-
CD33 monoclonal antibody linked to calicheamicin, a potent
antitumor antibiotic [18]. GO binds to CD33, an antigen
expressed on the surface of >90 % of AML blast cells.
Binding of GO is followed by internalization and toxin release
intracellularly leading to DNA damage and cell death [19]. In
studies of older patients with AML in first relapse, tolerable
toxicity and a response rate of 30 % was reported following
two infusions of GO 9 mg/m2, although full platelet recovery
did not occur in roughly half of responders [20]. These results led
to the drug regulatory approval in the United States for use in
older patients in first relapse for whom standard therapy was
unsuitable, setting the stage for its evaluation in patients with
newly diagnosed high-risk MDS. Our group developed a pro-
spective randomized trial combining two infusions of GO 6 mg/
m2 followed by standard remission-induction chemotherapy in
fit older patients [21]. This combination provided no benefit
compared to the control arm and appeared too (hemato)toxic in
patients older than 70 years. Patients with secondary AMLyoun-
ger than 70 years might be an exception [22]. Based on this
experience, we selected the GO dosage of 5 mg/m2 as a single
infusion on day 7 of the chemotherapy regimen [21, 23].
Patients and methods
Patients and eligibility
Thirty-one patients were registered in this study between
January 2003 and March 2006. One patient was ineligible.
Therefore, a total number of 30 patients were evaluable. The
patients had to meet the following disease criteria: (1) high-
risk MDS, defined as refractory anemia with excess of blasts
in transformation (RAEBt), RAEB>10 % BM blasts, other
forms of MDS with multiple (≥3) chromosomal abnormalities
or chromosome seven abnormalities and/or severe cytopenias
defined as follows: neutrophil count <0.5×109/l and/or plate-
let count <20×109/l; (2) chronic myelomonocytic leukemia
(CMMoL) with >5 % BM blasts or with >16×109/l neutro-
phils or with 2.6×109/l monocytes in the blood; (3) secondary
AML after overt MDS of more than 6 months duration. In
addition, the following criteria were required: age 16 to
70 years and adequate renal and liver function, defined as
1.5×upper limit of normal (ULN). Patients who had already
received chemotherapy and/or radiotherapy were not eligible.
All participants gave their informed consent. The study was
registered in clinicaltrials.gov (NCT00077116).
Study design
The cytarabine in combination with gemtuzumab ozogamicin
(IAGO) study was a phase II study carried out by the
European Organization for Research and Treatment of
Cancer (EORTC) Leukemia group and the Gruppo Italiano
Malattie Ematologiche dell Ádulto (GIMEMA).
The primary objective of this trial was to assess the feasi-
bility, toxicity profile, and antileukemic/anti-MDS activity of
GO in combination with a standard chemotherapy regimen
consisting of idarubicin and cytarabine in previously untreated
patients with high-risk MDS or sAML developing after a pre-
ceding period with MDS during 6 months.
Secondary objectives were to monitor hepatotoxicity, in
particular veno-occlusive disease (VOD), to determine the
severity of pancytopenia and duration of recovery in patients
who reached complete remission or CR with incomplete he-
matopoietic recovery (CRi).
Patients who met eligibility criteria had to be prospectively
registered at the EORTC Headquarters in Brussels, Belgium.
The remission-induction course consisted of a continuous
infusion of cytarabine 100 mg/m2/day for 10 days in combi-
nation with idarubicin 12 mg/m2/day on days 1, 3, and 5 as 5-
min infusions and GO on day 7 as a 1-h infusion at the dose
level of 5 mg/m2 (IAGO).
Response assessment was planned around day 31 after the
start of the induction course. The revised recommendations of
the Internat ional Working Group for Diagnosis ,
Standardization of Response Criteria, Treatment Outcomes,
and Reporting Standards for Therapeutic Trials in MDS [24]
were used. A CR required normalization of the marrow blasts
(less than 5 %) and recovery of normal hematopoiesis with a
neutrophil count of 1×109/l or more and a platelet count of
100×109/l or more in addition to disappearance of all clinical,
laboratory, or radiologic evidence of disease. CRi had criteria
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similar to CR but with neutrophils between 0.5×109 and 1×
109/l and/or platelet counts between 50×109 and 100×109/L.
Partial remission (PR) required blood recovery as for CR but
with both a decrease in marrow blasts of at least 50 % and not
more than 25 % abnormal cells in the marrow.
In case PR was achieved after the first course, a similar
second remission-induction course was given. In case of CR
or CRi after one or two induction courses, a single consolida-
tion course was recommended consisting of intermediate-dose
cytarabine (500 mg/m2 every 12 h in a 2-h infusion, on days
1–6) and idarubicin (10 mg/m2/day as 5-min infusion, on days
4, 5, 6) to be followed by either an allogeneic HSCT or an
autologous HSCT [17].
Reasons to stop treatment in the protocol: normal comple-
tion of the protocol after one or two courses IAGO, ineligibil-
ity, non-compliance of the patient, excessive toxicity, death,
and loss to follow-up (LFU).
Endpoints
The main endpoints were the best complete response (CR/
CRi) rate after one or two courses of IAGO and severe toxicity
rate observed during or after the completion of IAGO. The
secondary endpoint(s) were the following: survival and
progression-free survival (PFS) from start of treatment.
Overall survival (OS) was calculated, from the date of start
of treatment until date of death (whatever the cause). Patients
still alive were censored at the moment of last visit/contact.
PFS was calculated from the start of the first course of
IAGO until first date of relapse in patients who reached CR/
CRi or progression or until death (whatever the cause and
whichever occurred first). Patients still alive, in first CR/CRi
(i.e., without relapse), have been censored at the moment of
last visit/contact.
Registered and assessed for eligibility (n=31) 
Excluded (ineligible) (n=1)
Registered & Eligible (n=30)
Started intervention (n=30)
Discontinued intervention
Normal completion (n=13)
Excessive toxicity (n=6)
Treatment failure (n=11)
Response to IAGO
CR/CRi (n=8/5)
Failure (n=12)
Early death (n=5)
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Event-free survival
No progression (n=3)
Progression/relapse  (n=19)
Death in CR/no relapse (n=3)
Death without CR/no progression (n=4)
Fig. 1 Treatment plan and flow diagram
Table 1 Patient characteristics and survival rates at 1 and 2 years
Patient characteristics All patients (%) Survival (SE)
At 1 year At 2 years
All patients (M/F) 30 (21/9) 53 (9) 27 (8)
Age <55 years 44 (17) 33 (16)
Age ≥55 years 57 (11) 24 (9)
Performance status (WHO, 0–4)
0 17 – –
1/2 3 – –
MDS/sAML classification 21 48 (11) 24 (9)
RAEB-1 1 – –
RAEB-2 12 – –
CMML <5 % marrow blasts 1 – –
CMML ≥5 % marrow blasts 2 – –
RAEBt/sAML 14 64 (15) –
Hemoglobin (g/dl) <10 25 – –
Hemoglobin (g/dl) ≥10 5 – –
All nucleated cells <1.8×109/l 17 – –
All nucleated cells ≥1.8×109/l 3 – –
Platelets <100×109/l 21 – –
Platelets ≥100×109/l 9 – –
Cytogenetics (IPSS)
Good 10 90 (9) 40 (15)
Intermediate 9 56 (17) 33 (16)
Poor 7 0 0
ND/failure 4 50 (25) 25 (22)
IPSS
Intermediate-1 2 50 (35) 50 (35)
Intermediate-2 6 67 (19) 33 (19)
Poor 13 39 (13) 15 (10)
sAML 9 67 (16) 33 (16)
Interval from diagnosis to start of treatment
≤2 months 15 – –
>2 months (range 2–53) 15 – –
CRIANT score (points)
0–20 2 (7) 54 (14) 23 (12)
20−<50 13 (43) 47 (13) 20 (10)
≥50 15 (50) 47 (13) 33 (16)
SE standard error, RAEB refractory anemia with excess of blasts, CMML
chronic myelomonocytic leukemia, RAEBt RAEB in transformation,
sAML secondary acute myeloid leukemia, IPSS international prognostic
scoring system, CRIANT Score for details, see BMethods^ section
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Adverse events for each treatment course were recorded
according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (version 2.0).
Statistical design and methods
A Bryant-Day one-step design was used, including response
(CR/CRi) and excessive toxicity as the primary endpoint. The
following design parameters were considered:
& P0 is the largest CR/CRi probability which, if true, implies
that the therapeutic activity does not warrant further inves-
tigation of the regimen (IAGO). In the present trial, P0 has
been taken as 50 %.
& P1 is the lowest CR/CRi probability which, if true, implies
that the therapeutic activity does warrant further investi-
gation of the regimen provided acceptable severe acute
toxicity occurrence. In the present trial, P1 has been taken
as 75 %.
& (1-T0) is the smallest severe toxicity occurrence probabil-
ity which, if true, implies that the therapeutic toxicity is
unacceptable and the regimen does not warrant further
investigation. In the present trial, (1-T0) was taken as
50 %.
& (1-T1) is the largest severe toxicity occurrence probability
which, if true, implies that the therapeutic toxicity is ac-
ceptable and the regimen does warrant further investiga-
tion provided acceptable response rate. In the present trial,
(1-T1) was taken as 20 %.
& Beta error: the accepted probability of rejecting from fur-
ther trials a regimen with a true CR/CRi rate at least equal
to P1 and a true toxicity rate equal to or lower than (1-T1).
In the present trial, beta was taken as 0.10.
& Alpha error: the accepted probability of recommending
for further investigation a regimen with a true CR/CRi rate
equal to or lower than P0. It is also the accepted probabil-
ity of recommending for further trials a regimen with a
true severe toxicity rate equal to or higher than (1-T0).
In the present trial, the two alphas were taken as 0.10.
Based on these parameters, a total of 28 patients had to be
assessed for overall response and toxicity, and the following
decision rule had to be applied:
– If ≤17 (17/28=60.7 %), CR/CRis were observed, or if
≥11 (11/28=39.3 %), patients had severe toxicities, the
conclusion that IAGO is not enough active or is too toxic,
and should not be further investigated; otherwise, the
conclusion will be that IAGO is active and feasible, and
should be further investigated in this patient population.
A total of 31 patients has been finally been entered, in order
to cope with the exclusion of ineligible patients or of those
who did not start IAGO course. Among them, one patient was
considered to be ineligible by the study coordinator because of
incorrect diagnosis.
The time to event distributions (PFS and OS) were estimat-
ed using the Kaplan-Meier technique, and the standard errors
Table 3 Overview of outcome of nine patients with severe toxicities
Pt nr Duration survival (days) Main complication/reason off protocol
2 23 Febrile neutropenia leading to diffuse intravascular coagulation and to liver and renal failure; VOD not likely
6 32 Cardiac arrest
9 11 Pulmonary infiltrates; died from pulmonary failure due capillary leakage
13 1129 VOD; normal completion of protocol
20 1254+ Bilateral interstitial pneumonitis + normal completion
24 37 Lung infection, pulmonary insufficiency, and multi-organ failure
25 1035+ Iatrogenic hematothorax+normal completion
26 103 Grade 3 bilirubin elevation and liver lesions; grade 3 infection
29 36 Cerebral hemorrhage day 35; persisting thrombocytopenia
Table 2 Overview of toxicities during IAGO-1 course
Type of toxicity All grades Grades 3–4
All 30
Allergy 3 –
Hypertension –
Cardiac 5
Fatigue 16 7
Skin rash 5 2
Anorexia 15 4
Stomatitis/mucositis 13 4
Hemorrhage 4 2
Veno-occlusive disease Not applicable 1
Febrile neutropenia 9 9
Elevated bilirubin 16 5
Elevated creatinine 5 –
Elevated AST 18 2
Elevated ALT 16 2
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(SE) of the estimates were obtained via the Greenwood for-
mula. SAS 9.3 software (SAS Institute, Cary, NC) was used
for the statistical analyses.
The CRIANTscore was used to analyze the outcome accord-
ing to adapted prognostic criteria [2]. The score was created
based on the weight expressed in points of five criteria: cytoge-
netics (good, 0; intermediate, 20; poor, 40; unknown, 20),
WBC×109/l (<25, 0; ≥25, 20), age in years (≤45, 0; 45–55,
20; >55, 22), antecedent hematological disorder in months (≤6,
0; >6, 13), and number of cytopenias (0–2, 0; 3, 15). The
CRIANT score distinguished three risk groups: low risk, <20
points; intermediate risk, 20–49 points; and high risk, ≥50 points.
Results
Patient characteristics are shown in Table 1. The median age
was 58 years with a range from 21 to 66 years. Fourteen
patients had progressed to RAEBt [5] or secondary AML
[9]. All 30 eligible patients started the planned treatment
(Fig. 1). All patients received the full dosage of idarubicin,
two patients received a slightlymodified dosage of cytarabine,
and one patient a modified dosage of GO. Three patients re-
ceived a second course of IAGO after a PR to the first course.
Side effects
Side effects occurred in 25 patients during and after the first
course, including grade 3 to 4 toxicities in nine patients (see
Table 2). Besides fatigue, the most prominent toxicity con-
cerned liver toxicity, as shown by elevated bilirubin levels in
16 patients, including grade 3 to 4 in five patients. One case of
clinically relevant VOD has been diagnosed during the first
course of IAGO. This patient recovered completely, and he
could complete his treatment (see Table 3). Two out of the
three patients who received the second course developed se-
vere liver toxicity as shown by grade 3–4 elevated bilirubin
levels, but these patients did not develop VOD. Five (17 %)
patients died within 40 days after start of IAGO-1 due to
treatment related toxicities; for details, see Table 3.
Responses and duration of hypoplasia
Thirteen (43, 90 % CI (28, 60 %)) patients achieved a major
response, including eight patients with CR and five patients
with CRi (Fig. 1). Among the latter group, one patient
achieved PR after one course and entered CRi after two
Table 5 Post-remission therapy
and outcome Pt nr Response Type of SCT SCT
a Relapsea Survivala: cause of deathb
4 CR Auto 120 209 269
10 CR No 336 490
11 CR Auto 194 No 203: infection
13 CRi No 414 1129
15 CRi No No 1463c: CR
16 CR Allo 173 No 1420c: CR
17 CR Auto 127 132 160
19 CR Allo 205 No 441: GVHD
20 CRi Allo 576 471 1254c: second CR
22 CR No 305 405
23 CR Allo 160 No 168: NRM
25 CRi No No 1035c: CR
28 CRi Allo 103 No 1042c: CR
31 Failure Allo 161 Progression 827c: active disease
CR complete remission, CRi CR with incomplete recovery of platelets and leukocytes
a Number of days after starting treatment
b Active disease, if not mentioned specifically
c Patient still alive at last follow-up
Table 4 Hematopoietic recovery after first course of IAGO in 13
patients with CR or CRi
Recovery from start of IAGO Medium number of days
(95 % confidence intervals)
PMN >0.5×109/l 30 (28 to 32)
PMN >1.5×109/l 35 (31 to 43)
Platelets >50×109/l 29 (28 to NR)
Platelets >100×109/l 42 (28 to NR)
PMN polymorphic nucleated cells, NR not reached
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courses of the IAGO schedule. CR or CRi only occurred in
patients with good and intermediate cytogenetic risk score
according to IPSS (six out of 10 and five out nine, respective-
ly), while none of the seven patients with poor-risk cytogenet-
ic characteristics achieved CR in this study. The hematopoietic
recovery of patients who achieved CR or CRi was clearly
delayed as shown by the median recovery of neutrophils to
0.5×109/l of 30 days and of the platelets to >50×109/l of
29 days. For further details, see Table 4. Thirteen patients
(43 %) had a normal completion of the protocol consisting
of CR or CRi (Fig. 1). The other patients went off protocol
due to toxicity in six patients or due to treatment failure in 11
patients (37 %) (Fig. 1).
Post-remission therapy
All 13 patients with CR/CRi received consolidation therapy
which was followed by allogeneic HSCT in five patients and
autologous HSCT in three patients. Another patient who failed
to respond to the induction also received an allogeneic trans-
plantation. Five patients are alive without evidence of disease,
including one patient (nr 20) in second CR after alloSCT; for
Fig. 2 a Overall survival after
treatment with IAGO and post-
remission therapy. b Progression-
free survival after treatment with
IAGO and post-remission therapy
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details, see Table 5. Three patients have died in CR due to
complications after HSCT: two patients after alloHSCT and
one patient after autoHSCT.
Outcome and prognostic factors
At the time of final evaluation, four patients (13 %) were still
alive without signs of progression and two additional patients
were alive either with active disease or in second CR
(Table 5). Seventeen patients have died with active disease
and seven patients due to toxicity, including three patients in
CR. The median follow-up was 3.4 years. The median surviv-
al was 1.09 years (95 % CI 0.75 to 1.57). The survival rate at
1 year from start of treatment was 53% (SE 9%) and at 2 years
was 27 % (SE 8 %) (Table 1, Fig. 2a).
The median PFSwas 5.1 months (95% CI 1.6 to 10.8), and
the PFS rate at 1 year was 27 % with SE of 8 % (Fig. 2b).
Age (<55 versus ≥55 years) had no impact on survival
(Table 1). None of the seven patients with IPSS poor-risk
cytogenetic characteristics was alive at 1 year after start of
IAGO, while the 1-year survival in patients with good or in-
termediate risk cytogenetics was 90.0 % (SE 9 %) and 56 %
(SE 17 %), respectively; for details and 2-year survival rates,
see Table 1 and Fig. 3. The percentage of marrow blasts,
subdivided according to less than 20 % or 20 % and more
did not influence survival, with a 1-year survival rate of
47 % (SE 11) and 64 % (SE 15 %), respectively. The prog-
nostic importance of IPSS regarding survival was weak, prob-
ably due to the important weight allocated to the percentage of
marrow blasts and/or due to the limited number of patients in
each IPSS subgroup (Table 1). Fifty percent of the patients
were classified as poor-risk according to the recently devel-
oped CRIANT risk score [2] and only two patients as good-
risk patients. The survival of the poor-risk and intermediate
risk patients was similar (Table 1).
Discussion
In view of the observed CR/CRi rate of 43 % (13 out of 30
patients) with a 90 % CI of (27.9, 59.8 %), which did not
contain the targeted CR/CRi rate of 75 %, the Bryant-Day
one-step (negative) decision rule of this study was met. This
CR rate is lower than the generally observed remission rates
after various intensive chemotherapy regimens [12, 17, 20, 25,
26]. This indicates that the IAGO schedule was not sufficient-
ly active to warrant further exploration in this category of
patients.
The major cause of treatment failure in this study was in-
sufficient efficacy of the IAGO schedule. Similar studies, ex-
ploring new schedules in high-risk MDS patients, have result-
ed in higher CR rates, including the 71%CR rate in the FLAG
schedule (fludarabine, high dose cytarabine, and G-CSF) [26].
Several randomized studies of GO combined with intensive
chemotherapy have been performed in patients with elderly
primary AML. A meta-analysis of five prospective studies (in
total 3325 patients) [27] showed that addition of GO did not
increase the proportion of patients entering CR with an odds
ratio (OR) of 0.91 and a 95 % confidence interval (CI) of
0.77–1.07 (p=0.3). However, the addition of GO significantly
improved survival (OR 0.90; 95 % CI 0.82–0.98, p=0.03),
although the 5-year OS difference was only around 3 %:
35.5 % (GO arm) versus 32.2 % (control group). In addition,
patients with adverse cytogenetic characteristics did not ben-
efit from the addition of GO in contrast to patients with favor-
able or intermediate cytogenetic features [27]. The great ma-
jority of patients in this meta-analysis were patients with de
novo AML. Only two studies [28, 29] included patients with
secondary AML and only one study included high-risk MDS
patients [29].
Toxicity was an important contributing factor to the gen-
eral outcome in this study, since six out of the 17 patients
went off protocol due to toxicity. Toxicity was fatal within
40 days after starting treatment in five patients (16.7 %).
Overall, the observed grade 3–4 toxicity was 33.3 %, and its
90 % CI (16.6, 46.5 %) did not cover the inacceptable tox-
icity rate of 50 %. In an earlier study of our group [30], we
treated a younger age group (median age of 47 years) of 194
patients with the same remission-induction regimen
(idarubicin, cytarabine, and etoposide (ICE)) with the ex-
ception of etoposide which has been replaced by GO in the
present study. The CR rate in that study was 54 % and 29
patients (16 %) died during the remission-induction phase,
which is comparable to the 17 % observed in the current
study [30]. The CR rate was 58 % in a more recent study
[17] utilizing the same schedule (ICE) as the previous study
[30]. The median patient age of the patients in this study
was lower (52 versus 58 years), but the percentage of pa-
tients with poor-risk cytogenetics was higher in the previ-
ous study: 31 versus 23 % in the IAGO study [17]. None ofFig. 3 Overall survival in cytogenetic subgroups according to IPSS
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the seven patients with poor-risk cytogenetic characteristics
entered CR/CRi, and none of these patients was alive at
1 year after starting treatment. In the previous study, three
risk groups were distinguished: a good-risk group with a
score <20, an intermediate risk group with a score 20–
<50, and a poor-risk group with a score ≥50. The 5-year
estimated survival rates were 69 % (SE=10.2 %), 37 %
(SE=5.6 %), and 5 % (SE=2.1 %) for the three groups,
respectively [2]. Poor-risk cytogenetic characteristics had
a pronounced weight in this scoring system. Only two pa-
tients in this study were classified as good risk and 15 pa-
tients as poor-risk. The survival of the intermediate and
poor-risk patients was not significantly different (p=0.29),
but the numbers are small (Table 1).
GO has been administered as a single dose of 5 mg/m2 on
day 7 of the chemotherapy schedule in the current study. It is
possible that a more fractioned schedule with a higher total
dose of GOmight be a more effective strategy which may take
advantage of CD33-re-expression that occurs after initial ex-
posure to the GO [31]. The French Alfa-group utilized a GO
schedule of 3 mg/m2/day on days 1, 4, and 7 during induction
chemotherapy in patients aged 50–70 years with untreated
primary AML. Complete response was 81 % and event-free
survival was 40.8 % compared to 17.1 % in the control group
(p value=0.003) [32]. This benefit was also apparent in pa-
tients with unfavorable cytogenetic characteristics, but the im-
pact of complex karyotype has not been analyzed separately
[32]. In addition, early mortality seems to be reduced if a dose
of 3 g/m2 is used either as a single dose or in a fractionated
schedule [27].
Conclusions
The observed CR/CRi’s rate of 43% led to the conclusion that
IAGO is not sufficiently active to warrant further exploration
in high-risk MDS and secondary AML evolved fromMDS. In
addition, patients with poor cytogenetic features had a very
poor outcome caused by a complete absence CR and CRi rate
in this phase II study. Alternative schedules with more frac-
tionated schedules of GO may result in better outcome in this
population of high-risk MDS or AML evolved from MDS.
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